

# NCIC CLINICAL TRIALS GROUP

## GASTROINTESTINAL

### DISEASE SITE COMMITTEE MEETING

#### AGENDA

## OPEN SESSIONS

Venue: Duluth Room  
Date: Sunday, May 2<sup>nd</sup> 2010  
Time: 8:00 am – noon  
Chair: Dr. Derek Jonker

8:00 am **WELCOME AND INTRODUCTION** Dr. D. Jonker

---

8:15 am **SELECTED APPROVED / OPEN TRIALS FOR DISCUSSION**

**CO.21:** A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with Early Stage Colon Cancer: A Randomized Controlled Trial (CHALLENGE) Dr. C. Booth / Dr. S. Gill

**CO.20:** A Phase III Randomizes Study of Brivanib Alaninate (BMS-582664) in Combination With Cetuximab (Erbix<sup>®</sup>) versus Placebo in Combination with Cetuximab (Erbix<sup>®</sup>) in Patients Previously Treated with Combination Chemotherapy for Metastatic Colorectal Carcinoma Dr. L. Siu

**CRC.3** (ECOG E5202): A Randomized Phase III Study Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers. Dr. S. Koski

**CRC.5** (CALGB 80405): A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5FU / Leucovorin with Bevacizumab, or Cetuximab, or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum Dr. S. Berry / Dr. D. Jonker

**CRC.6** (CALGB 80702): A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant Folfox Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer Dr. D. Jonker / Dr. S. Gill

**HEC.1** (CALGB 80802): Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Dr. J. Knox

**ES.2** (TROG 03.01): A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and palliation of Dysphagia in Patients Treated with Radiotherapy versus Chemo-Radiotherapy Dr. Rebecca Wong

**NEC.2** (CALGB-80701) Randomized Phase II Study of Bevacizumab Alone, in Combination With Everolimus, or in Combination With Temozolomide in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.

Dr. L. Siu

**PA.5** (GERCOR LAP07) Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib.

Dr. M. Moore / Dr. C. O'Callaghan

**9:30 am PRESENTATION AND PRIORITIZATION OF NEW CONCEPTS**

This is the most critical discussion of the meeting. Concepts here will have been vetted and brought forward by working group chairs as being ready for consideration by the Clinical Trials Committee. These presentations will include survey results (if available) and will be followed by a show-of hands prioritization opportunity. Not all trials presented here would be able to move forward to the CTC. Maximum participation is critical.

**10:00 am BREAK**

**10:15 am PRESENTATION AND PRIORITIZATION OF NEW CONCEPTS (CONTINUED)**

**11:00 am DISEASE ORIENTED WORKING GROUP REPORTS (ONLY AS REQUIRED)**

**Colon DOG**  
**Rectal DOG**  
**Esophageal / Gastric DOG**  
**Pancreas DOG**  
**Hepatobiliary DOG**  
**Neuroendocrine DOG**

Dr. D. Jonker / Dr. S. Gill  
 Dr. N. Baxter/ Dr. T. Vuong  
 Dr. Rebecca Wong / Dr. C. Kollmannsberger  
 Dr. M. Moore / Dr. S. Gallinger  
 Dr. O. Bathe / Dr. J. Knox  
 Dr. L. Siu

**IND REPORT**

Dr. D. Jonker

**GI INTERGROUP UPDATE**

Dr. D. Jonker

**11:45 am CLOSING REMARKS & ADJOURNMENT**

Dr. D. Jonker

**12:00 pm CLOSED SESSION: GI EXECUTIVE MEETING**

Dr. D. Jonker